Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (GB:0A4C)
LSE:0A4C
Holding GB:0A4C?
Track your performance easily
0A4C Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.12 - $14.82
Previous Close$6.2
Volume2.13K
Average Volume (3M)11.38K
Market Cap
$437.09M
Enterprise Value$272.18M
Total Cash (Recent Filing)$164.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Nov 05, 2024EPS Estimate
-$0.36Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,070,951
10 Day Avg. Volume8,021
30 Day Avg. Volume11,377
Standard Deviation0.60
R-Squared0.00306
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)2.90
Price to Sales (P/S)1082.57
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue665.47
Enterprise Value/Gross Profit638.92
Enterprise Value/Ebitda-2.77
Forecast
1Y Price Target
$21.20Price Target Upside241.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Altimmune News
PremiumCompany Announcements
David Drutz to Exit Altimmune Board at Next Annual Meeting
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPemvidutide’s superior liver fat reductions and cleaner safety have the potential to show some of the best histology data the NASH field has seen.
Drug DevelopmentManagement is continuing development of an oral formulation of pemvi, offering the same weight loss and potency alongside tolerability profile, allowing differentiation from mono GLP1 oral small molecule programs.
Market PositionThe scarcity of similar candidates in biotech companies positions pemvidutide favorably in the market.
Bears Say
Clinical Trial ResultsSurvodutide has superior weight loss and improvement in HbA1c but at the cost of worse tolerability, which is not expected to improve significantly in Phase 3.
Drug DevelopmentThe company is discontinuing development of hepatitis B candidate HepTCell which we considered upside, and thus has no impact on our valuation.
Drug TolerabilitySurvodutide data show one of the worst tolerability profiles for a GLP-based candidate.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.83% Insiders
11.34% Mutual Funds
<0.01% Other Institutional Investors
74.04% Public Companies and
Individual Investors
0A4C FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest share price was $2.12 and its highest was $14.82 in the past 12 months.
What is Altimmune Inc’s market cap?
Currently, no data Available
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Nov 05, 2024 which is in 30 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Aug 08, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.349 by -$0.001.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Notavailable dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -$0.36.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 71,070,950 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.349. Following the earnings report the stock price went up 14.089%.
Which hedge fund is a major shareholder of Altimmune Inc?
Among the largest hedge funds holding Altimmune Inc’s share is Ardsley Advisory Partners. It holds Altimmune Inc’s shares valued at 2M.
---
Altimmune Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.20 (241.88% Upside)
$21.20 (241.88% Upside)
Blogger Sentiment
Bullish
GB:0A4C Sentiment 97%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $110.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
148.20%
12-Months-Change
Fundamentals
Return on Equity
-63.29%
Trailing 12-Months
Asset Growth
-5.44%
Trailing 12-Months
Company Description
Altimmune Inc
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
0A4C Earnings Call
Q2 2024
0:00 / 0:00
---
0A4C Stock 12 Month Forecast
Average Price Target
$21.20
▲(241.88% Upside)
Technical Analysis
Best Analysts Covering 0A4C
1 Year
1 Year Success Rate
14/34 ratings generated profit
1 Year Average Return
+1.67%
reiterated a buy rating 2 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +1.67% per trade.
---